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There is an urgent need for a vaccine to combat the hepatitis C
virus (HCV) pandemic, and induction of broadly neutralizing mono-
clonal antibodies (bNAbs) against HCV is a major goal of vaccine
development. Even within HCV genotype 1, no single bNAb effec-
tively neutralizes all viral strains, so induction of multiple neutralizing
monoclonal antibodies (NAbs) targeting distinct epitopes may be
necessary for protective immunity. Therefore, identification of
optimal NAb combinations and characterization of NAb interac-
tions can guide vaccine development. We analyzed neutralization
profiles of 12 human NAbs across diverse HCV strains, assigning
the NAbs to two functionally distinct clusters. We then measured
neutralizing breadth of 35 NAb combinations against genotype
1 isolates, with each combination including one NAb from each
neutralization cluster. Many NAbs displayed complementary neu-
tralizing breadth, forming combinations with greater neutralization
across diverse strains than any individual bNAb. Remarkably, one of
themost broadly neutralizing combinations of two NAbs, designated
HEPC74/HEPC98, also displayed enhanced potency, with interactions
matching the Bliss independence model, suggesting that these NAbs
inhibit HCV infection through independent mechanisms. Subsequent
experiments showed that HEPC74 primarily blocks HCV envelope
protein binding to CD81, while HEPC98 primarily blocks binding to
scavenger receptor B1 and heparan sulfate. Together, these data
identify a critical vulnerability resulting from the reliance of HCV on
multiple cell surface receptors, suggesting that vaccine induction of
multiple NAbs with distinct neutralization profiles is likely to enhance
the breadth and potency of the humoral immune response against HCV.
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Despite the development of highly effective direct-acting an-tivirals (DAAs) for treatment of hepatitis C virus (HCV)
infection, a vaccine is still needed to combat the HCV pandemic.
Most infected individuals are unaware of their status and may
continue to expose others (1). Most infected persons do not have
access to DAAs, and currently available treatments do not pro-
vide protection against reinfection after cure (2–4).
One objective of HCV vaccine development is the induction of
broadly neutralizing monoclonal antibodies (bNAbs) against the
virus. Dozens of bNAbs have been isolated from infected hu-
mans. These bNAbs target overlapping but distinct epitopes on
the HCV envelope proteins (E1 and E2) and neutralize diverse
HCV strains (5–15). Combinations of bNAbs are protective
against HCV challenge in animal models (9, 10, 16, 17), and
spontaneous clearance of HCV without treatment in humans is
associated with early development of bNAbs (18–20), suggesting
that bNAbs may play a key role in immune-mediated control of
human HCV infection.
While some human bNAbs show impressive neutralizing
breadth (5, 9, 20–22), HCV is an extraordinarily diverse virus, so
no single bNAb neutralizes all viral strains (21–25). This re-
sistance makes it less likely that vaccine induction of any single
bNAb would provide adequate protection against a diverse HCV
quasispecies challenge. Therefore, induction of multiple neu-
tralizing monoclonal antibodies (NAbs) targeting distinct epi-
topes may be necessary. However, several studies have suggested
that some antibodies against HCV are antagonistic (26–28), and
the most advantageous NAb combinations have not yet been
identified. New studies are needed to better define NAb inter-
actions, and to identify optimal NAb combinations.
We and others have shown that human NAbs have distinct
patterns of relative neutralizing potency across diverse HCV
strains, also called neutralization profiles (20–22). Two NAbs
could have enhanced neutralizing breadth in combination if their
neutralization profiles across diverse HCV strains are comple-
mentary, so that viral strains resistant to one NAb are sensitive to
the other. The efficacy of NAb combinations is also influenced by
potency against viral strains recognized by both NAbs. Synergy or
antagonism between NAbs can be defined relative to either the
Loewe additivity model (29, 30), which assumes that two inhibitors
have similar mechanisms or compete for the same binding site, or
the Bliss independence model (31), which assumes that inhibitors
have independent binding sites and independent mechanisms.
To identify optimal NAb combinations, we analyzed neutraliza-
tion profiles of 12 NAbs, assigning them to two functionally distinct
neutralization clusters. We then measured neutralization of 11 ge-
netically and antigenically diverse genotype 1 HCV pseudoparticles
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(HCVpp) by 35 NAb combinations, with each combination in-
cluding one NAb from each neutralization cluster. For a subset
of combinations, we compared experimental neutralization to
neutralization predicted by the Loewe additivity and Bliss in-
dependence models, to identify synergy, additivity, antagonism,
or independence between NAbs.
Results
Selection of NAb Combinations for Analysis.We selected a panel of
12 human NAbs targeting distinct epitopes on HCV E2. This
panel includes some of the most broadly neutralizing anti-HCV
antibodies described to date, as well as less broadly neutralizing
mAbs, with binding epitopes that overlap to varying degrees (Fig.
1A and Table S1). We analyzed the neutralizing breadth of each
of these NAbs in prior studies using a diverse panel of 19 geno-
type 1 HCVpp (20, 22–24). We previously showed that these
quantitative neutralization data across diverse strains comprise a
neutralization profile for each NAb, which can be compared
among NAbs to understand functional relationships (22). We
calculated pairwise Spearman correlations between neutraliza-
tion profiles of these 12 NAbs and performed hierarchical clus-
tering analysis using these pairwise correlations (Fig. 1B). As we
have seen in prior analyses, these NAbs segregated into two
distinct neutralization clusters. We tested all possible combina-
tions comprising one NAb from each neutralization cluster
(35 combinations), since we hypothesized that these combina-
tions would have greatest potential for complementarity.
Selection of a Diverse and Representative Genotype 1 HCVpp Panel.
We previously developed a panel of 19 genotype 1 HCVpp that
was selected to maximize genetic diversity among functional
E1E2 genes (18, 22). To date, we have used this panel of 19
HCVpp to measure neutralizing breadth of 32 mAbs with
binding epitopes across E1E2, including the mAbs in the current
study (20, 22). Using these data, we identified a subset panel of
11 HCVpp that recapitulates the full range of neutralization
sensitivity of the larger panel of 19 HCVpp (Fig. S1A). Neu-
tralizing breadth of each of 32 mAbs measured using either the
full 19 HCVpp panel or the 11 HCVpp subset are very similar.
The mean breadth of these mAbs (percentage of HCVpp in the
panel that were neutralized >50% at a mAb concentration of
10 μg/mL) was 38% (range 0 to 95%) using the 19 HCVpp panel
and 36% (range 0 to 91%) using the 11 HCVpp panel (P = not
significant by paired t test). Strains in the 11 HCVpp panel differ
at an average of 74 amino acids (13%) [range 26 (5%) to 121
(22%)], and isolates are distributed across a phylogenetic tree
including 634 genotype 1a and 1b reference sequences from
GenBank (32) (Fig. S1B). Variability in 20 amino acid windows
across E1E2 is nearly identical for the 11 HCVpp panel, the
19 HCVpp panel, and in the reference set of 634 genotype 1
sequences (Fig. S1C). The panel of 11 HCVpp also contains 96%
of E1E2 amino acid polymorphisms present with at least 10%
frequency in the 634 genotype 1 reference sequences (Fig. S1D).
Since it appears to be representative of genotype 1 E1E2 diversity
at the level of conformational B cell epitopes, 20 amino acid
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Fig. 1. NAb binding epitopes and hierarchical clus-
tering. (A) The crystallized structure of the HCV E2
protein, strain H77, from Kong et al. (49) acquired
from Protein Data Bank, accession 4MWF, with colors
modified in PyMOL. The E2 structure is in gray, with
previously defined NAb binding residues identified by
alanine scanning highlighted in various colors. NAbs
targeting the magenta region bind to largely over-
lapping but distinct epitopes. Dashed lines indicate
regions missing from the crystal structure. The binding
epitope of HEPC90 is not known. (B) Hierarchical
clustering of NAbs based on neutralization profiling.
NAbs are colored-coded according to the scheme in
A. For each NAb, relative neutralization of each of 19
HCVpp was measured to generate a neutralization
profile. Pairwise Spearman correlations (r) between
NAb neutralization profiles were then calculated to
identify functional similarities among NAbs. Circles at
each intersection of the heat map were scaled by the
magnitude of the correlation between the indicated
NAbs. R values approaching +1 (dark blue) and −1
(dark red) indicate positive or negative correlations,
respectively. Hierarchical clustering analysis using
these pairwise correlations is depicted as a tree.
Numbers at tree nodes are approximately unbiased
(AU) test values (51), which indicate strength of
support for a particular cluster.
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windows, and the majority of single amino acid polymorphisms, we
elected to use this 11 HCVpp panel for neutralization breadth
testing of NAb combinations.
Combinations Show Greater Neutralization Across Diverse Strains
than Individual NAbs. We measured neutralization of the 11
HCVpp panel by 35 NAb combinations or by their individual
component NAbs. Each NAb combination was tested at a total
concentration of 10 μg/mL, consisting of 5 μg/mL of each NAb,
and each individual NAb was tested separately at 10 μg/mL
against the same panel. We have shown previously that per-
centage neutralization of HCVpp by NAbs at 10 μg/mL can be
used to make reliable quantitative comparisons of both the
number of HCVpp recognized by each NAb (breadth) and the
quantitative level of neutralization of each HCVpp (potency)
(16, 20, 22–25). We first compared neutralization by all indi-
vidual NAbs to neutralization by all NAb combinations. The
median percentage neutralization of HCVpp in the panel by
individual NAbs at 10 μg/mL was 50%, while the median per-
centage neutralization by NAb combinations at the same total
concentration was significantly greater at 62% (P < 0.01, un-
paired two-tailed t test) (Fig. 2A).
We then evaluated neutralization by each combination in-
dividually (Fig. 2B). Median percentage neutralization of HCVpp in
the panel by NAb combinations ranged from 84% (AR3C/AR5A)
down to 15% (HEPC46/HEPC98), while median percentage neu-
tralization by individual NAbs ranged from 72% (HEPC74) down to
2% (HEPC46). Notably, 17 of 35 NAb combinations had a higher
median percentage neutralization of HCVpp in the panel than either
of their component NAbs tested individually. Eleven combinations
produced median percentage neutralization between that of their
two component NAbs. Only 7 of 35 combinations showed lower
median percentage neutralization than either component NAb
tested individually. Overall, these results suggest that many NAb
combinations show greater neutralization across diverse strains than
their individual component NAbs tested at the same total antibody
concentration, and relatively few combinations are disadvantageous.
Combinations Have Complementary Neutralizing Breadth. Next, we
compared neutralizing breadth of individual NAbs and combi-
nations, with breadth defined as the number of HCVpp neu-
tralized by greater than 50%. Individual NAbs neutralized a
median of 6 of the 11 HCVpp (55%; range 0 to 8 HCVpp), while
NAb combinations neutralized a median of 7 HCVpp (64%;
range 3 to 9 HCVpp) at the same total antibody concentration
(P < 0.05, unpaired two-tailed t test) (Fig. 3A). Four combina-
tions, HEPC74/HEPC98, HEPC74/AR4A, HC84.26/AR5A, and
HC84.26/AR4A, neutralized 9 of the 11 HCVpp (81%), exceed-
ing the neutralizing breadth of any individual bNAb tested.
By examining the neutralization profiles of these NAbs individually
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Fig. 2. Combinations show greater neutralization
across diverse strains than individual NAbs. Percent
neutralization of 11 HCVpp by individual NAbs at
10 μg/mL or NAb combinations at 10 μg/mL total
concentration (5 μg/mL of each NAb). (A) Percent
neutralization of 11 HCVpp by all individual NAbs (n =
132; 12 NAbs × 11 HCVpp) and all NAb combinations
(n = 385; 35 NAb combinations × 11 HCVpp). Each
symbol indicates mean percent neutralization of an
individual HCVpp, measured in duplicate. **P < 0.01 by
unpaired, two-sided t test. (B) Neutralization of 11
HCVpp by each NAb combination, with combinations
arranged from highest to lowest median percentage
neutralization. Horizontal lines indicate medians, bars
indicate 25th to 75th percentile, and whiskers in-
dicate range. Gray circles indicate the median per-
cent neutralization value of each component NAb in
the combination when tested individually at 10 μg/mL
(x, combinations with median percent neutraliza-
tion greater than that of either component NAb; +,
combinations with median percent neutralization
between that of component NAbs; −, combinations
with median percent neutralization less than either
component NAb).
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or in combination, we observed clear evidence of complemen-
tation, as all HCVpp that were neutralized by at least one of the
two NAbs in a combination also were neutralized by the com-
bination (Fig. 3B). Complementation was also observed between
most other NAb combinations (Fig. S2). Taken together, these
results suggest that NAbs from distinct neutralization clusters
have enhanced neutralizing breadth in combination due to
complementation, with some combinations displaying greater
breadth than any individual bNAb.
Of these 35 combinations tested, we selected three for more
detailed analyses: one with greater percentage neutralization of
HCVpp in the panel than either of its component NAbs
(HEPC74/HEPC98), one with median percentage neutralization
between that of its two component NAbs (HEPC3/HEPC90),
and one with lower median percentage neutralization than either
of its component NAbs (HC84.26/HC33.4). As a positive control
for Loewe additivity, we also performed all subsequent analyses
with a combination of two cluster 1 NAbs (HEPC3/HEPC74)
with largely overlapping epitopes.
Binding Competition. E1E2-binding competition ELISAs were
performed with the four NAb combinations of interest. For each
NAb combination, we selected one to two E1E2 strains from
HCVpp that were neutralized potently by each NAb in the com-
bination. Competition was defined as a 50% or greater reduction
in binding of a biotinylated NAb in the presence of a blocking
NAb. Competitive binding with self was used as a positive control,
and noncompetitive binding with nonspecific human IgG served as
a negative control. HEPC3 and HEPC74, the component NAbs in
the control combination, bound competitively to both 1a53
E1E2 and 1b14 E1E2 (Fig. 4A), which was expected given their
largely overlapping binding epitopes (Fig. 1A). In contrast,
HEPC74 and HEPC98 bound to 1a154 E1E2 noncompetitively
(Fig. 4B), which also was expected given their nonoverlapping
binding epitopes (Fig. 1A). HEPC3 and HEPC90 bound non-
competitively to both 1a142 E1E2 and 1a53 E1E2 (Fig. 4C). In-
terestingly, HC33.4 and HC84.26, which have adjacent but
nonoverlapping binding epitopes, showed unidirectional binding
competition. HC84.26 reduced binding by HC33.4 by 53%, while
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Fig. 3. NAbs have complementary neutralizing
breadth. (A) Neutralization of 11 HCVpp by individual
NAbs at 10 μg/mL or NAb combinations at 10 μg/mL
total concentration (5 μg/mL of each NAb). HCVpp
were counted as neutralized if infectivity was re-
duced by more than 50%. Colors indicate the two
NAbs in each combination. Horizontal lines indicated
medians. Neutralization profiles of circled combina-
tions are shown in B. *P < 0.05 by unpaired, two-
sided t test. (B) Neutralization profiles of the NAb
combinations with greatest neutralizing breadth.
Values are mean percent neutralization by 10 μg/mL
of each individual NAb or 10 μg/mL total concentra-
tion of NAb combinations, measured in duplicate.
Pink indicates NAb/HCVpp tests with percent neu-
tralization of >50%. Arrows indicate complementary
neutralization by the two NAbs in each combination.
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HC33.4 only reduced the binding of HC84.26 by 16% (Fig. 4D).
This unidirectional binding competition between these NAbs was
also observed in a prior study (13).
HEPC3/HEPC74, HEPC3/HEPC90, and HC84.26/HC33.4 Neutralization
Follows a Pattern Consistent with Loewe Additivity. To better un-
derstand interactions between these NAb pairs, we compared
neutralization by serial dilutions of NAb combinations to neu-
tralization predicted by the Loewe additivity or Bliss in-
dependence models, which can be calculated from neutralization
curves of individual component NAbs. We developed a script in
Python to perform these calculations (see Materials and Meth-
ods). The Loewe additivity model assumes that two inhibitors
have similar mechanisms or compete for the same binding site.
Experimental neutralization by a combination matching the
Loewe prediction indicates additive effects of the component
NAbs, while neutralization greater than or less than the Loewe
prediction indicates synergy or antagonism, respectively (30, 33).
Experimental neutralization by a combination matching the Bliss
independence prediction suggests that the component NAbs
have both independent binding sites and independent mecha-
nisms of inhibition (30, 33). We analyzed combination effects
relative to the Loewe additivity model, since many NAbs have
overlapping binding sites and common inhibitory mechanisms.
However, mechanisms of neutralization for many NAbs are not
known, and we hypothesized that some might have independent
mechanisms, since HCV entry requires multiple cell surface re-
ceptors, including CD81, scavenger receptor-B1 (SR-B1), clau-
din, and occludin (34). We therefore analyzed combination
effects relative to the Bliss independence model as well.
As expected, neutralization of strain 1a53 HCVpp by the con-
trol combination HEPC3/HEPC74 followed a Loewe additivity
pattern (Fig. 5A). Experimental neutralization differed from that
predicted by the Loewe model at only one of nine antibody con-
centrations, while experimental neutralization differed signifi-
cantly from the Bliss prediction at four of nine concentrations (P <
0.05 for each point, paired two-tailed t test/Holm−Sidak correc-
tion for multiple comparisons). These results were confirmed with
three additional independent experiments (Fig. S3A). HEPC3/
HEPC74 neutralization of a second HCVpp, 1b14, also primarily
followed Loewe additivity (Fig. 5A). Experimental neutralization
differed from neutralization predicted by the Loewe model at only
one of nine concentrations, and differed significantly from the
Bliss prediction at two of nine concentrations (P < 0.05 for each),
with a trend toward difference from Bliss at two additional points.
These results also were confirmed with three additional in-
dependent experiments (Fig. S3B). Additive effects between these
NAbs were expected, since they bind to largely overlapping epi-
topes and compete for binding to E1E2 (Fig. 4A).
Neutralization by HEPC3/HEPC90 also matched the Loewe
additivity prediction (Fig. 5B). Experimental neutralization of
strain 1a142 HCVpp by this combination differed from the Loewe
prediction at only 1 of 10 concentrations, and differed significantly
from the Bliss prediction at 5 of 10 concentrations (P < 0.05 for
each). This result was confirmed with two additional independent
experiments (Fig. S3C). Experimental neutralization of a second
strain, 1a53 HCVpp, differed from Loewe-predicted neutraliza-
tion at zero of nine concentrations, and differed significantly from
the Bliss prediction at one of nine concentrations (P < 0.05 for
each), with a trend toward difference from Bliss at two additional
points. These results also were confirmed in a second independent
experiment (Fig. S3D). Since HEPC3 and HEPC90 do not com-
pete for E1E2 binding, neutralization matching Loewe additivity
suggests that these NAbs may act through common or dependent
inhibitory mechanisms.
HC84.26/HC33.4 neutralization of 1a38 HCVpp primarily fol-
lowed Loewe additivity as well, except that at the highest antibody
concentrations the combination demonstrated slight synergy rel-
ative to the Loewe prediction. At these two concentrations, ex-
perimental neutralization was significantly greater than the Loewe
prediction, but significantly lower than the Bliss prediction (P <
0.05 for each) (Fig. 5C). This result was confirmed in a second
independent experiment (Fig. S3E), and these results agree with
analysis of this combination in a prior study (13).
HEPC74/HEPC98 Neutralization Is Synergistic Relative to the Loewe
Additivity Model and Follows Bliss Independence. Neutralization
by serial dilutions of HEPC74/HEPC98 was tested using both
replication competent cell culture virus (HCVcc) and HCVpp.
Remarkably, HEPC74/HEPC98 not only demonstrated strong
synergy relative to the Loewe model prediction, but neutraliza-
tion by the combination also matched the Bliss independence
prediction very closely (Fig. 6). Experimental neutralization of
1a53 HCVcc exceeded Loewe-predicted neutralization at 7 of
10 concentrations (P < 0.05 for each), while it differed from
Bliss-predicted neutralization at only 1 of 10 concentrations.
Notably, neutralization of strain 1a53 HCVpp closely repro-
duced results obtained with 1a53 HCVcc, in agreement with our
prior studies showing that neutralization of HCVpp accurately
represents neutralization of E1E2-matched replication competent
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Fig. 4. Competition binding between NAbs. Bind-
ing of 2 μg/mL of biotinylated NAbs on the y axis
(“Binding NAbs”) to the indicated E1E2 proteins was
measured in the presence or absence of the NAbs on
the x axis (“Blocking NAbs”) at a concentration of
20 μg/mL (HEPC3, HEPC74, HEPC98, HEPC90/1a53 E1E2)
or 50 μg/mL (HC84.26, HEPC90/1a142 E1E2). Values
shown are binding of the biotinylated NAb in the
presence of blocking NAb, relative to binding in the
absence of blocking NAb, averaged from duplicate
measurements. Pink boxes indicate competition, which
was defined as a relative binding value of <0.50. Com-
petition between HEPC3 and HEPC74 (A), HEPC74 and
HEPC98 (B), HEPC3 and HEPC90 (C), and HC33.4 and
HC84.26 (D).
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virus (22, 24). Experimental neutralization of strain 1a53 HCVpp
significantly exceeded the neutralization predicted by the Loewe
additivity model at six of nine concentrations (P < 0.05 for each),
while it differed significantly from the Bliss prediction at only
two of nine concentrations. This result was supported by three
additional independent experiments (Fig. S3F).
HEPC74/HEPC98 neutralization of a second strain, 1a154
(H77) HCVpp, was also synergistic relative to the Loewe model
and also followed Bliss independence. Experimental neutraliza-
tion significantly exceeded Loewe-predicted neutralization at six
of seven concentrations (P < 0.05 for each), and differed from
Bliss-predicted neutralization at zero of seven concentrations.
This result also was supported by two additional independent
experiments (Fig. S3G). Taken together, these results suggest
that HEPC74 and HEPC98 are potent in combination because
the component NAbs have independent inhibitory mechanisms.
HEPC74 and HEPC98 Have Distinct Mechanisms of Inhibition. We
assessed the binding sites of HEPC74 and HEPC98 on E2 rel-
ative to previously identified sites of E2 binding to two primary
HCV receptors, CD81 (35) and SR-B1 (36), and an accessory
receptor, heparan sulfate (36) (Fig. 7A). The binding site of
HEPC74 overlaps with the E2−CD81 binding site, while the
binding site of HEPC98 overlaps with the E2−SR-B1 and E2−
heparan sulfate binding sites.
Given data showing that hypervariable region 1 (HVR1), the
binding site of HEPC98, can mask the CD81 binding site (37),
which is also the binding site of HEPC74, we surmised that
binding of HEPC98 might enhance or inhibit binding of HEP74
by exposing or occluding the HEPC74 epitope. To rule this out,
we quantitated E1E2 binding of serial dilutions of HEPC74 in
the presence or absence of HEPC98, and binding of serial di-
lutions of HEPC98 in the presence or absence of HEPC74,
C
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confirming that binding of one antibody does not enhance or
inhibit binding of the other (Fig. 7B).
To further assess mechanisms of neutralization, we measured
timing of activity of each NAb relative to timing of HCVpp cell
surface attachment. For comparison, we also measured timing of
activity of blocking antibodies against CD81 and SR-B1, and of
CL58, a peptide inhibitor of claudin, which is a cell surface mol-
ecule required for entry after virus binding to CD81 and SR-B1
(38) (Fig. 7C). All inhibitors showed maximal or near-maximal
activity when added immediately after binding of HCVpp to
hepatoma cells (T0). Interestingly, CL58 and anti−SR-B1 showed
reduced inhibitory activity when incubated with cells and then
removed from medium before HCVpp attachment (T-30), which
could be due to low-affinity binding or inaccessibility of binding
sites before virus attachment. HEPC74, HEPC98, anti-CD81, and
anti−SR-B1 all showed progressively declining activity relative to
T0 when added 30, 60, or 120 min after HCVpp attachment, while
CL58 maintained significantly more activity than the other in-
hibitors at these later time points. Together, these data suggest
that HEPC74 and HEPC98 block HCV entry at an early post-
attachment step, upstream of claudin engagement, with timing of
maximal activity similar to anti-CD81 and anti−SR-B1 mAbs.
We then quantified for each NAb inhibition of strain 1a154
(H77) soluble E2 (sE2) binding to CD81 or SR-B1 on the surface
of Chinese hamster ovary (CHO) cells (Fig. 7D). We first con-
firmed that each NAb bound sE2 in ELISA, and also serially
diluted sE2 to define the linear range of sE2 binding to CD81−
CHO and SR-B1−CHO cells (Fig. S4). A concentration of
sE2 within this linear binding range was preincubated with serial
dilutions of either HEPC74, HEPC98, or nonspecific human
IgG, then used to stain CHO cells. HEPC74 inhibited binding to
CD81 (IC50 log10[1.00] μg/mL) and inhibited binding to SR-
B1 somewhat less potently (IC50 log10[1.53] μg/mL). As expected
given its binding epitope, HEPC98 only showed significant in-
hibition of binding to SR-B1 (IC50 log10[1.20] μg/mL).
Finally, we measured inhibition of sE2 binding to heparan
sulfate, an accessory HCV receptor. As predicted by their
E2 binding epitopes, HEPC98 inhibited sE2 binding to heparan,
while HEPC74 had no effect. Overall, investigations of HEPC74
and HEPC98 inhibitory mechanisms confirm that HEPC74 binds
at the E2−CD81 binding site and inhibits E2−CD81 binding
more potently than E2−SR-B1 binding, while HEPC98 binds at
the E2−SR-B1 and E2−heparan binding sites and primarily in-
hibits E2−SR-B1 binding as well as E2−heparan binding. These
notable differences between mechanisms of neutralization may
explain the observation that neutralization by this combination
follows Bliss independence.
Discussion
In this study, we assigned 12 human NAbs to two distinct func-
tional clusters and tested 35 NAb combinations for neutralization
of a panel of 11 genetically and antigenically diverse HCVpp.
Many NAbs displayed complementary neutralizing breadth,
forming combinations with greater neutralization across the
HCVpp panel than any individual bNAb. The pairing of
HEPC74/HEPC98 showed both enhanced neutralizing breadth
and enhanced potency relative to its component NAbs. Remarkably,
neutralization with this combination matched neutralization pre-
dicted by the Bliss independence model, suggesting that these
NAbs act through independent mechanisms. Our investigations
of these inhibitory mechanisms suggest that HEPC74 primar-
ily blocks E2−CD81 binding, while HEPC98 primarily blocks
E2−SR-B1 and E2−heparan binding.
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Fig. 6. HEPC74/HEPC98 neutralization follows Bliss independence. Median
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models. Statistically significant differences between the experimental in-
hibition and Loewe or Bliss predictions are indicated with red and orange
asterisks, respectively. Experimental neutralization values are the means of
duplicate measurements. Loewe and Bliss values are the means of four in-
dividual predictions made at each antibody concentration using data from
individual NAb neutralization, which was measured in duplicate. Error bars
indicate SDs. Statistical significance was determined by paired t tests, cor-
rected for multiple comparisons using the Holm−Sidak method. (A) HEPC74/
HEPC98 tested against 1a53 HCVcc. (B) HEPC74/HEPC98 tested against 1a53
HCVpp. (C) HEPC74/HEPC98 tested against 1a154 HCVpp.
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The discovery of Bliss independence between HEPC74 and
HEPC98 is remarkable, since both NAbs bind to the E2 protein.
In contrast, many inhibitor pairs that follow Bliss independence,
such as drugs used in combination for HIV or HCV treatment,
target distinct viral proteins with different functions (33). These
data identify a critical vulnerability resulting from the reliance of
HCV on multiple cell surface receptors, suggesting that vaccine
induction of both HEPC74-like and HEPC98-like antibodies
could be particularly effective.
A recent study found antagonism between a murine mAb,
H77.16, which binds to HVR1 of E2, and a set of human bNAbs,
including a bNAb designated HC-11. These data led to the con-
clusion that vaccine induction of NAbs against HVR1 might be
undesirable (26). In contrast, in our study, the combination of
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HEPC74 and a human NAb HEPC98, which also targets HVR1,
was synergistic and broadly neutralizing, showing that human an-
tibodies targeting HVR1 can be advantageous. The contrast be-
tween the findings of these two studies is interesting, since
H77.16 and HEPC98 bind to overlapping epitopes, as do HC-11
and HEPC74. These contrasting results may be the result of greater
spatial separation between E2-bound HEPC98 and HEPC74 rel-
ative to E2-bound H77.16 and HC-11. This model is plausible,
since recent studies have suggested that this region of E2 is highly
flexible (39, 40), so NAbs with overlapping epitopes might bind to
different epitope conformations or bind with different angles of
approach. The structural relationship between these adjacent
neutralizing epitopes certainly warrants further investigation.
Several recent publications have discussed vaccination strategies
designed to favor induction of NAbs against specific E2 epitopes,
and limit formation of antibodies against other epitopes. These
include molecular scaffold approaches that present single epitopes
(41), or truncation of E2 to eliminate variable regions and better
expose conserved epitopes (26, 42). In contrast, data presented
here suggest that vaccination with full-length E1E2 could also be
advantageous, since it might induce combinations of NAbs with
distinct mechanisms of neutralization, leading to neutralizing
synergy and complementary neutralizing breadth. Alternatively,
epitope scaffolds might be designed to present both HEPC74-like
and HEPC98-like epitopes.
Several studies have previously evaluated synergy/antagonism
between anti-HCV mAbs using models based on Loewe addi-
tivity. Carlsen et al. (21) observed synergy between HC84.26 and
AR4A, a NAb combination also included in our study. We ob-
served complementation of neutralizing breadth between these
NAbs, further suggesting that this pairing may be advantageous.
Keck et al. (13) previously evaluated another combination,
HC84.26/HC33.4. In agreement with the Keck study, we ob-
served unidirectional competition for E2 binding between the
mAbs, as well as additive neutralization at most antibody con-
centrations, with slight synergy relative to Loewe at the highest
antibody concentrations. Interestingly, however, this was one of
the less broadly neutralizing combinations in our study (Fig. 3A).
This result may be explained, in part, by the presence in the
HCVpp panel of four strains with leucine or isoleucine poly-
morphisms at the 442 locus in E2, which confer resistance to
HC84.26 (16, 22). HC84.26 resistance may be slightly exagger-
ated by this panel, since isoleucine (I) or leucine (L) polymor-
phisms at position 442 were present in 36% of isolates in this
panel of 11 HCVpp, while they are present in only 17% of iso-
lates in the reference panel of 634 genotype 1a and 1b sequences
from GenBank. Importantly, however, HC33.4 also showed only
marginal potency against some of these same strains, and thus
did not fully complement this deficiency in HC84.26 breadth.
Together, these results highlight the importance of comple-
mentarity of neutralizing breadth in addition to synergy/antago-
nism when identifying ideal NAb combinations.
A limitation of this study is the use of only genotype 1 HCVpp
or HCVcc to measure neutralizing breadth and synergy. We have
chosen to focus on this genotype since it is most prevalent
worldwide, and no bNAb isolated to date effectively neutralizes all
genotype 1 HCV strains (9, 22, 23, 43). While we have selected a
panel of genotype 1 HCVpp that is genetically and phenotypically
diverse, future studies are needed to confirm and extend these
findings using larger panels of genotype 1 HCVpp, as well as HCV
from other genotypes. This approach will be particularly impor-
tant for further evaluation of combinations including HEPC98,
since it binds to a highly variable region of E2.
Overall, our evaluation of 35 NAb combinations suggests that
enhanced neutralizing breadth by combinations of NAbs from
distinct functional neutralization clusters is common. We also
discovered a potent and broadly neutralizing combination of
NAbs with interactions following Bliss independence, suggesting
that NAbs binding to distinct epitopes on E2 may inhibit HCV
infection through independent mechanisms. Together, these data
define superior NAb combinations, identify a critical vulnerability
resulting from the reliance of HCV on multiple cell surface re-
ceptors, and suggest that vaccine induction of multiple bNAbs with
distinct neutralization profiles is likely to enhance the breadth and
potency of the humoral immune response against HCV.
Materials and Methods
See SI Materials and Methods for detailed experimental procedures.
Cell Lines. HEK293T cells and Hep3B cells were obtained from American Type
Culture Collection. CHO cells expressing recombinant human CD81 or
SR-B1 were a gift fromMatthew Evans, Icahn School of Medicine, Mount Sinai,
New York.
Antibodies. MAbs CBH-5 (11), HC84.26 (5), and HC33.4 (13) were a gift of
Steven Foung, Stanford University School of Medicine, Stanford, CA. MAbs
AR3B, AR3C (10), AR4A, and AR5A (9) were a gift of Mansun Law, Scripps
Research Institute, La Jolla, CA. All other antibodies were isolated in the
laboratory of J.E.C. (20).
Hierarchical Clustering of NAbs. NAbs were grouped into functionally related
clusters based upon their neutralization profiles as previously described
(20, 22).
E1E2 Sequence Analysis. Evolutionary analyses were conducted in Molecular
Evolutionary Genetics Analysis version 7 (MEGA7) (44). Diversity plots were
generated using VarPlot v1.2 (45) (https://sray.med.som.jhmi.edu/SCRoftware/
VarPlot/) with 1aa steps and 20 aa windows. Inclusion of reference panel
polymorphisms in the 11 and 19 HCVpp panels was calculated using a pre-
viously described reference alignment from GenBank (32) and the package
“seqinr” in R, as previously described (22).
HCVpp Production and Neutralization. HCVpp were produced by lipofectamine-
mediated transfection of HCV E1E2, pNL4-3.Luc.R-E-, and pAdVantage
(Promega) plasmids into HEK293T cells as previously described (22, 46, 47).
Neutralization assays were performed as described previously (48).
HCVcc Production and Neutralization. Generation of an HCVcc chimera
expressing the 1a53 E1E2 proteins was previously described (24, 25). HCVcc
neutralization assays were performed in triplicate as previously described (24, 25).
Identification of Synergy/Additivity/Antagonism or Independence Using the
Loewe Additivity and Bliss Independence Models. Briefly, for four selected
NAb combinations, two HCVpp were selected for each NAb combination
that were at least partially neutralized by 10 μg/mL of each NAb in that
combination [fraction unaffected (fu) < 0.3, except HEPC3/1b14 (0.63),
HEPC90/1a53 (0.65)]. The combination of HEPC74/HEPC98 was also tested
using 1a53 strain HCVcc. Neutralization by serial twofold dilutions of NAbs
combined in a fixed ratio adjusted for their relative IC50s was measured (30).
Neutralization by serial dilutions of individual component NAbs was si-
multaneously measured, using the same antibody concentrations tested in
the NAb combination neutralization curve. The fu and fraction affected (fa)
values from the individual NAb neutralization curves were used to calculate
neutralization for each NAb combination predicted by the Loewe addi-
tivity and the Bliss independence models.
Quality Control for Loewe/Bliss Analysis. Only individual NAb curves with
linear relationships on median effect plot with R squared of >0.85 were used
to calculate Loewe additivity and Bliss independence curves (Fig. S5). To
confirm that NAbs were combined in optimal ratios to allow discrimination
between Loewe additivity and Bliss independence, predicted Loewe and
Bliss curves for each combination were confirmed to be statistically different
from each other for at least three antibody concentrations (Fig. S5).
Binding Competition Assays.MAb binding to E1E2 was quantitated using ELISA
as previously described (7).† Blocking NAbs were added at either 50 μg/mL or
20 μg/mL, and biotinylated binding NAbs were added at their EC75.
†Netski DM, et al., 11th International Symposium on Hepatitis C Virus and Related Viruses,
October 3−7, 2004, Heidelberg, Germany.
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Timecourse Inhibition Experiments. HCVpp were incubated with cells at 4 °C
for 4 h to allow attachment without entry, then cells were washed and
shifted to 37 °C (Time 0) to allow subsequent entry steps. Inhibitors HEPC74,
HEPC98, CL58 peptide (38), anti-CD81 mAb (BD 555675), anti−SR-B1 mAb
(BD 610882), or isotype control mAb (BD 560550) were added 30 min before
HCVpp addition to cells (T-30), immediately after attachment (T0), or 30, 60,
or 120 min after HCVpp attachment.
Expression of sE2. A truncated, soluble form of strain 1a154 (H77) E2 ecto-
domain (sE2), encompassing residues 384 to 645, as previously described (49),
was cloned into a mammalian expression vector (phCMV3_Ig Kappa_HIS, a
gift of Leopold Kong, The Scripps Research Institute, La Jolla, CA) and
expressed by transfection into HEK293T or HEK293-6E cells.
sE2 Binding to CHO Cells. CHO−CD81 and CHO−SR-B1 binding experiments
were carried out as previously described (23, 50).
sE2 Binding to Heparan Sulfate. Heparan binding experiments were carried
out essentially as previously described (36).
Statistical Analysis. All statistical analyses were carried out in Prism v7.02
(Graphpad Software). Neutralizing breadth and neutralizing potency were
compared by unpaired, two-sided t test. Experimental neutralization values
were compared with Loewe-predicted and Bliss-predicted values by multiple
t tests, corrected for multiple comparisons by the Holm−Sidak method,
without assumption of consistent SD between points.
Study Approval. All protocols were approved by the Institutional Review
Board of the Johns Hopkins Hospital, and informed consent was obtained
from all study participants.
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